Quantcast

Heptares Presentation at Future Leaders in the Biotech Industry to be Webcast

March 26, 2014

LONDON and BOSTON, March 26, 2014 /PRNewswire/ –

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and
development company, notes that a company presentation to be given by its Chief Executive
Officer, Malcolm Weir, at BioCentury Future Leaders in the Biotech Industry
[https://www.biocentury.com/conferences/futureleaders/dates ] on 28 March 2014 will be
webcast live. The presentation will take place at 9.30am ET in room 302/303 at the
Millennium Broadway Hotel & Conference Center, New York City, NY, USA. The webcast will be
available from this time at http://www.heptares.com/downloads.

For a full list of events at which Heptares will be present, please visit

http://www.heptares.com

About Heptares Therapeutics

Heptares creates new medicines targeting clinically important, yet historically
challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked
to a wide range of human diseases. Leveraging our proprietary structure-based drug design
technology platform, we have built an exciting pipeline of novel drug candidates with the
potential to transform the treatment of serious diseases, including Alzheimer’s disease,
ADHD, diabetes, schizophrenia, and migraine. Our pharmaceutical partners include Cubist,
MorphoSys, Takeda, AstraZeneca and MedImmune, and we are backed by Clarus Ventures, MVM
Life Science Partners, Novartis Venture Fund, the Stanley Family Foundation and Takeda
Ventures. To learn more about Heptares, please visit http://www.heptares.com

HEPTARES is a registered trademark in the EU, Switzerland, US and Japan;

StaR is a registered trademark in the EU and Japan.

SOURCE Heptares Therapeutics


Source: PR Newswire



comments powered by Disqus